Top Markets
#1 Black Phoenix Black Phoenix +167.57%
#2 Islamic Coin Islamic Coin +158.27%
#3 Glidr Glidr +84.34%
#4 Acurast Acurast +33.17%
#5 Test Test +21.48%
#6 Cryptopia Cryptopia +20.92%
#7 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +18.26%
#8 Quantum Resistant Ledger Quantum Resistant Ledger +16.56%
#9 stake.link stake.link +9.38%
#10 Wrapped Bitcoin (PulseChain) Wrapped Bitcoin (PulseChain) +9.37%
Coin of the day
Black Phoenix Black Phoenix
Tetapan
Bahasa
MALAY
Mata wang
USD
Tema
Genomic Vision S.A. Genomic Vision S.A.

Genomic Vision S.A.

GV
Kedudukan dalam Saham #41547
Headquartered in Bagneux, France, and established in 2004, Genomic Vision S.A.... Headquartered in Bagneux, France, and established in 2004, Genomic Vision S.A. is a molecular diagnostics and technology company focused on developing sophisticated tools for analyzing individual DNA molecules. These innovations serve both scientific research and in vitro diagnostic purposes. A cornerstone of their offerings is the FiberVision molecular combing platform, which streamlines DNA analysis workflows. This platform integrates FiberComb, a system for stretching single DNA molecules onto vinyl silane glass, with a FiberVision scanner designed to acquire high-resolution images of entire coverslip surfaces automatically. The data is then processed by FiberStudio software, which detects hybridization signals, analyzes results, and generates reports. Supporting these systems, the company provides the FiberPrep DNA extraction kit, producing purified DNA for combing, alongside essential accessories such as custom-treated glass carriers and disposable DNA reservoirs. Genomic Vision also offers specialized FiberProbes, including "Genomic Morse Code" sets for detecting mutations associated with hereditary breast and ovarian cancer (BRCA), as well as for identifying and characterizing structural variations related to hereditary nonpolyposis colorectal cancer, particularly anomalies in the flanking regions of MMR genes. Additionally, their molecular combing services enable clients to validate planned gene editing events, identify substantial unintended modifications (exceeding 1 kilobase), and precisely quantify on-target versus off-target genetic changes. The company reinforces its position through strategic partnerships, including an alliance with Quest Diagnostics and development and research collaborations with La Timone Hospital and the Institut Pasteur, respectively.
Harga Saham
$0.00196068
Disegerakkan terakhir: 2023-12-01
Modal Pasaran
$16.64K
Perubahan (1 hari)
0.01%
Perubahan (1 tahun)
0.00%
Negara
FR
Perdagangan Genomic Vision S.A. (GV)

Kategori

Healthcare
Nisbah P/E bagi Genomic Vision S.A. (GV)
Nisbah P/E pada 2026 TTM: 0
Menurut laporan kewangan dan harga saham terkini Genomic Vision S.A., nisbah P/E semasa (TTM) ialah 0. Pada akhir 2026, syarikat mempunyai nisbah P/E sebanyak 0.
Sejarah nisbah P/E bagi Genomic Vision S.A. dari 2026 hingga 2026
Nisbah P/E pada akhir setiap tahun
Tahun Nisbah P/E Ubah
Tidak cukup data untuk tarikh yang disediakan.
Nisbah P/E untuk syarikat serupa atau pesaing
Syarikat Nisbah P/E Perbezaan Nisbah P/E Negara
Thermo Fisher Scientific Inc. Thermo Fisher Scientific Inc.
Thermo Fisher Scientific Inc.
TMO.US
 30.84 -
US
Danaher Corporation Danaher Corporation
Danaher Corporation
DHR.US
 34.53 -
US
WuXi AppTec Co., Ltd. WuXi AppTec Co., Ltd.
WuXi AppTec Co., Ltd.
603259.SS
 - -
CN
IDEXX Laboratories, Inc. IDEXX Laboratories, Inc.
IDEXX Laboratories, Inc.
IDXX.US
 40.90 -
US
Natera, Inc. Natera, Inc.
Natera, Inc.
NTRA.US
 -164.27 -
US
Cara membaca nisbah P/E

Nisbah Harga/Perolehan (P/E) mengukur hubungan antara harga saham syarikat dan pendapatan sesaham.
P/E yang rendah tetapi positif menunjukkan syarikat menjana keuntungan tinggi berbanding dengan penilaian semasa dan mungkin dinilai rendah. P/E negatif yang tinggi (hampir 0) menunjukkan kerugian besar.

Syarikat dengan P/E melebihi 30 atau negatif biasanya dilihat sebagai "saham pertumbuhan", bermaksud pelabur menjangkakan pertumbuhan atau keuntungan masa depan.

Syarikat dengan P/E positif di bawah 10 biasanya dianggap sebagai "saham nilai", bermaksud syarikat sudah menguntungkan dan tidak dijangka berkembang pesat.